A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Xisomab 3G3 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Xisomab 3G3 (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Aronora
- 20 Feb 2018 Status changed from active, no longer recruiting to completed.
- 08 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 08 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Jan 2018.